Anthony Nuara, MD, PhD, presents the case of a 32-year-old woman with vitiligo, covering her initial diagnosis and workup findings, ending this segment with her prescribed treatments and how shared decision-making lead to these choices.
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
Dermatology clinicians at a Case-Based Roundtable in Austin, Texas, discussed real-world strategies for sequencing topical therapy, phototherapy, and ruxolitinib cream across pediatric and adult vitiligo cases.